Onconova Therapeutics, Inc is a biotechnology business based in the US. Onconova Therapeutics shares (ONTX) are listed on the NASDAQ and all prices are listed in US Dollars. Onconova Therapeutics employs 11 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Onconova Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ONTX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Onconova Therapeutics stock price (NASDAQ: ONTX)Use our graph to track the performance of ONTX stocks over time.
Onconova Therapeutics shares at a glance
|Latest market close||$6.69|
|52-week range||$2.85 - $28.05|
|50-day moving average||$6.55|
|200-day moving average||$11.40|
|Wall St. target price||$35.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.81|
Buy Onconova Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Onconova Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Onconova Therapeutics price performance over time
|1 week (2021-07-18)||N/A|
|1 month (2021-06-29)||-4.70%|
|3 months (2021-04-29)||820.22%|
|6 months (2021-01-25)||N/A|
|1 year (2020-07-25)||N/A|
|2 years (2019-07-25)||N/A|
|3 years (2018-07-25)||N/A|
|5 years (2016-07-25)||N/A|
Onconova Therapeutics financials
|Gross profit TTM||$231,000|
|Return on assets TTM||-37.02%|
|Return on equity TTM||-84.72%|
|Market capitalisation||$85.4 million|
TTM: trailing 12 months
Shorting Onconova Therapeutics shares
There are currently 719,759 Onconova Therapeutics shares held short by investors – that's known as Onconova Therapeutics's "short interest". This figure is 25.7% down from 969,124 last month.
There are a few different ways that this level of interest in shorting Onconova Therapeutics shares can be evaluated.
Onconova Therapeutics's "short interest ratio" (SIR)
Onconova Therapeutics's "short interest ratio" (SIR) is the quantity of Onconova Therapeutics shares currently shorted divided by the average quantity of Onconova Therapeutics shares traded daily (recently around 1.0 million). Onconova Therapeutics's SIR currently stands at 0.69. In other words for every 100,000 Onconova Therapeutics shares traded daily on the market, roughly 690 shares are currently held short.
However Onconova Therapeutics's short interest can also be evaluated against the total number of Onconova Therapeutics shares, or, against the total number of tradable Onconova Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Onconova Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Onconova Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0486% of the tradable shares (for every 100,000 tradable Onconova Therapeutics shares, roughly 49 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Onconova Therapeutics.
Find out more about how you can short Onconova Therapeutics stock.
Onconova Therapeutics share dividends
We're not expecting Onconova Therapeutics to pay a dividend over the next 12 months.
Have Onconova Therapeutics's shares ever split?
Onconova Therapeutics's shares were split on a 1:15 basis on 20 May 2021. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Onconova Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Onconova Therapeutics shares which in turn could have impacted Onconova Therapeutics's share price.
Onconova Therapeutics share price volatility
Over the last 12 months, Onconova Therapeutics's shares have ranged in value from as little as $2.8515 up to $28.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Onconova Therapeutics's is 1.6942. This would suggest that Onconova Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Onconova Therapeutics overview
Onconova Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA.
Stocks similar to Onconova Therapeutics
Onconova Therapeutics in the news
Frequently asked questionsWhat percentage of Onconova Therapeutics is owned by insiders or institutions?
Currently 0.546% of Onconova Therapeutics shares are held by insiders and 23.078% by institutions. How many people work for Onconova Therapeutics?
Latest data suggests 11 work at Onconova Therapeutics. When does the fiscal year end for Onconova Therapeutics?
Onconova Therapeutics's fiscal year ends in December. Where is Onconova Therapeutics based?
Onconova Therapeutics's address is: 375 Pheasant Run, Newtown, PA, United States, 18940 What is Onconova Therapeutics's ISIN number?
Onconova Therapeutics's international securities identification number is: US68232V4059 What is Onconova Therapeutics's CUSIP number?
Onconova Therapeutics's Committee on Uniform Securities Identification Procedures number is: 68232V108
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert